Navigation Links
ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO

tor genotypes achieved an MTD of 400 mg/m2 of Quinamed weekly (three weeks on treatment followed by one week off treatment, repeated). Using these dosing regimens, 64% of rapid and intermediate acetylators and 77% of slow acetylators showed no dose-limiting drug toxicities or dose-delay/holds during treatment.

In a population of heavily pretreated patients who were refractory to multiple existing therapies and who had advanced tumors, there was evidence of antitumor activity in a range of tumor types. Three prostate cancer patients showed a decline in prostate specific antigen (PSA), with one of these achieving a partial response. Two patients with ovarian cancer achieved stable disease accompanied by a decline in the ovarian cancer biomarker CA125. One patient with gastrointestinal stromal tumor (GIST) demonstrated stable disease which was sustained over 18 monthly cycles of amonafide.

Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex said that the results were a significant step in the development of personalized medicines. “The data that Dr Kuhn presented today show very clearly that we now understand the effect of genotype on amonafide metabolism, and that we can dose patients to minimize the side effects of therapy. We are encouraged by the signs of anticancer activity across a range of tumor types in patients who had failed multiple prior therapies, and look forward to progressing Quinamed into further development for indications where the clinical need and commercial potential is greatest.”

Quinamed® is a registered trademark of ChemGenex Pharmaceuticals Limited.

About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)
ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes and obesity. ChemGenex harnesses t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:12/1/2008)...icy , , ROCHESTER, Minn., Dec. 1 /PRNewswi...ds the use of the drug therapy etanercept ineffect...ammation of the liver caused by excessive consumpt...shed in the December issue of Gastroenterology (...O ALERT: Additional audio and video resources, inc...
(Date:12/1/2008)...ay, December 9 at 11:00 am ET to Discuss Phase 2 S...ISCO, Calif., Dec. 1 S...biopharmaceutical company focused on the developme...ics, today announced new data from its studies of ...presented during the 50th American Society of Hema...
(Date:11/30/2008)...e-USNewswire/ -- Older adults who exercise regular...r number of small blood vessels in the brain, acco...eting of the Radiological Society of North America...University of North Carolina ( UNC) - Chapel Hill...ults who exercise to brain scans of those who do n...
(Date:11/28/2008)...tCall/ -- Eli Lilly and Company,(NYSE: LLY ) ha...(sNDA) from,the U.S. Food and Drug Administration...anagement of chronic pain. Lilly plans to resubmit...g data from a recently completed positive study,i... The decision does not affect duloxetine,s FDA-ap...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Barr Announces Approval of Generic Yasmin 28R 29 5282 1Barr Announces Approval of Generic Yasmin 28R 29 5282 2Barr Announces Approval of Generic Yasmin 28R 29 5282 3New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2025 1New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2025 2New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2025 3New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2025 4New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2025 5New Class of Drugs Might Treat Many Conditions 18938 1New Class of Drugs Might Treat Many Conditions 18938 2Kiwa Bio Tech 1st Quarter Revenues Increase 57 8 25 242 18 Million 5279 1Kiwa Bio Tech 1st Quarter Revenues Increase 57 8 25 242 18 Million 5279 2Kiwa Bio Tech 1st Quarter Revenues Increase 57 8 25 242 18 Million 5279 3
...e Skeletal Muscle More,Efficiently than Male Cells...e stem cells,derived from muscle have a greater ab...le cells, according to a study at Children,s,Hospi...eing published in the April 9 issue of the,Journal...fference,in regenerative capabilities of muscle st...
...007 - Inotek,Pharmaceuticals Corporation announced...eclinical animal data showing that the,administrat...tor,has a large protective effect on the survival ... a nuclear enzyme that directs the,repair of damag...epair enzymes and has potential applications for t...
Other Medicine Technology:The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem,Cells Work Better 2The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem,Cells Work Better 3Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3
(Date:12/2/2008)...unces integration of its,HealthURL Appliance with...are,Organizations. The EMC Open Systems Archive S...odular DICOM-compliant management platform that,a...uding medical images from,clinical and business a...ntegration with the MedCommons appliance unifies t...
(Date:12/2/2008)...onse Biomedical Corporation (TSX: RBM, OTCBB: RPBI... the Company,s RAMP(R) test to detect Respiratory ...linical study is expected to be used to support a ...n (FDA) and other regulatory jurisdictions for mar...or clinical use. The study is designed to demonstr...
(Date:12/2/2008)...Over Next Decade, According to a New Report from D...2 Decision Resources, one of the w...rmaceutical and healthcare issues, finds that the ...ust growth in the United States over the next deca...e new special report entitled Cellular Therapies,...
(Date:12/2/2008)...l/ -- China Sky One Medical,Inc. ("China Sky One...eading,fully integrated pharmaceutical company pr...public of China ("PRC"), announced today that Mr. ... Officer and Secretary and will,also serve on the... Zhang, who,had served as interim CFO since June,...
Breaking Medicine News(10 mins):Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 3Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 2Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 3Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 4Health News:Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3
... cancer survivors can halve the risk of dying from...se moderately regardless of their weight, suggest...er at the University of California, San Diego (UCS...nical Oncology, this is the first study to look at...
...chers at USC and Caltech have spectacularly slowed...ows general promise in pharmaceutical development ...ut how to make the fruit fly live longer. But the...have something for humans. As reported online in N...
...te Cancer is the most frequently diagnosed cancer ...th prostate cancer this year alone, and more than ...s Month, and with Fathers Day approaching, its a g... prostates healthy and be proactive about cancer p...
...ate department of Health today confirmed the death... virus. This is the first case in 2007 and it see... record number 177 people died due to the virus. ...West Nile this year, while no other state has had ...
Other Medicine News:Health News:Healthy Diet, Exercise can Halve the Risk of Mortality in Breast Cancer Survivors 2Health News:Super Fruit Fly may Harbor Hope for Human Longevity 2Health News:Tips to Maintain a Healthy Prostate 2Health News:First Case of West Nile Virus Death in Madison County 2
Portable - Battery Powered (6 size AA required). Fast, Lightweight Strain Gage Mechanism. Unit conversion (g, ct, oz, ozt, GN, dwt, mom, dwt, tael), Specific Gravity calculation, Piece Counting and P
Portable - Battery Powered (6 size AA required). Fast, Lightweight Strain Gage Mechanism. Unit conversion (g, ct, oz, ozt, GN, dwt, mom, dwt, tael), Specific Gravity calculation, Piece Counting and P
Small, comes in a compact carrying case, carrying pouch included.
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure.
Medicine Products: